Download PDF
CC BY-NC-ND 4.0 · South Asian J Cancer 2015; 04(01): 001-002
DOI: 10.4103/2278-330X.149900
Editorial

The changing face of acute myeloid leukemia therapeutics in the elderly population

Naval Daver
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
,
Jorge Cortes
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
› Author Affiliations Source of Support: Nill.
› Further Information
Also available at
  PDF Download Permissions and Reprints


Publication History

Article published online:
31 December 2020

© 2015. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, et al. Cancer statistics, 2006. CA Cancer J Clin 2006;56:106-30.
  • 2 Löwenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med 1999;341:1051-62.
  • 3 Juliusson G, Antunovic P, Derolf A, Lehmann S, Möllgård L, Stockelberg D, et al. Age and acute myeloid leukemia: Real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood 2009;113:4179-87.
  • 4 Kantarjian HM. Therapy for elderly patients with acute myeloid leukemia: A problem in search of solutions. Cancer 2007;109:1007-10.
  • 5 Kantarjian H, O′brien S, Cortes J, Giles F, Faderl S, Jabbour E, et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: Predictive prognostic models for outcome. Cancer 2006;106:1090-8.
  • 6 Nazha A, Ravandi F. Acute myeloid leukemia in the elderly: Do we know who should be treated and how? Leuk Lymphoma 2014;55:979-87.
  • 7 Appelbaum FR, Gundacker H, Head DR, Slovak ML, Willman CL, Godwin JE, et al. Age and acute myeloid leukemia. Blood 2006;107:3481-5.
  • 8 Büchner T, Berdel WE, Haferlach C, Haferlach T, Schnittger S, Müller-Tidow C, et al. Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: A study by the German Acute Myeloid Leukemia Cooperative Group. J Clin Oncol 2009;27:61-9.
  • 9 Kantarjian H, Ravandi F, O′Brien S, Cortes J, Faderl S, Garcia-Manero G, et al. Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. Blood 2010;116:4422-9.
  • 10 Menzin J, Lang K, Earle CC, Kerney D, Mallick R. The outcomes and costs of acute myeloid leukemia among the elderly. Arch Intern Med 2002;162:1597-603.11
  • 11 Burnett AK, Milligan D, Prentice AG, et al. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer. 2007;109: 1114-24.
  • 12 Kantarjian HM, Thomas XG, Dmoszynska A, Wierzbowska A, Mazur G, Mayer J, et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol 2012;30:2670-7.
  • 13 Thomas XG, Arthur C, Delaunay J, Jones M, Berrak E, Kantarjian HM. A post hoc sensitivity analysis of survival probabilities in a multinational phase III trial of decitabine in older patients with newly diagnosed acute myeloid leukemia. Clin Lymphoma Myeloma Leuk 2014;14:68-72.
  • 14 Fenaux P, Mufti GJ, Hellström-Lindberg E, Santini V, Gattermann N, Germing U, et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 2010;28:562-9.
  • 15 Dombret JF, Butrym A, Wierzbowska A, Selleslag D, Jang RK, Cavenagh J, et al. Results of a phase 3, multicenter, randomized, open-label study of azacytidine (AZA) vs conventional care regimens (CCR) in older patients with newly diagnosed acute myeloid leukemia (AML). Haematologica; Milan: European Hematology Association Annual Meeting Abstract; 2014. p. 788-9.
  • 16 Kantarjian HM, Jabbour E, Yee K, Kropf P, O′Connell C, Stock W, et al. First Clinical results of a randomized phase 2 Study Of SGI-110, a Novel Subcutaneous (SQ) Hypomethylating Agent (HMA), in Adult Patients With Acute Myeloid Leukemia (AML). Blood; New Orleans: American Society of Hematology Annual Meeting 2013, Abstract 122.
  • 17 Parikh SA, Kantarjian H, Garcia-Manero G, Jabbour E, Kadia T, Ravandi F , et al. Clofarabine plus low-dose cytarabine induction followed by consolidation with clofarabine plus low-dose cytarabine alternating with decitabine as frontline therapy for patients (pts) with Acute Myeloid Leukemia (AML) >=60 years (yrs). Blood; New Orleans: American Society of Hematology Annual Meeting 2009, Abstract 114.
  • 18 Kadia TM, Borthakur G, Ferrajoli A, Jain P, Jabbour E, Verstovsek S, et al. Phase II Trial Of Cladribine and Low-Dose AraC (LDAC) Alternating with decitabine in older patients with Acute Myeloid Leukemia (AML). Blood; New Orleans: American Society of Hematology Annual Meeting 2013, Abstract 122.
  • 19 Marcucci G, Haferlach T, Döhner H. Molecular genetics of adult acute myeloid leukemia: Prognostic and therapeutic implications. J Clin Oncol 2011;29:475-86.
  • 20 Rockova V, Abbas S, Wouters BJ, Erpelinck CA, Beverloo HB, Delwel R, et al. Risk stratification of intermediate-risk acute myeloid leukemia: Integrative analysis of a multitude of gene mutation and gene expression markers. Blood 2011;118:1069-76.